Detail akcie Mirum Rg Reg S-AI online

Business Summary: Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Mirum Pharmaceuticals Inc revenues increased 57% to $372.4M. Net loss decreased 73% to $17.6M. Revenues reflect Livmarli segment increase of 70% to $253.6M, Bile Acid Medicines segment increase of 35% to $118.8M. Lower net loss reflects Other Income (expense) net increase from $982K to $2.6M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$1.36 to -$0.36.